Lilly's Zepbound remains physicians' favorite, even as oral obesity launches alter landscape

Injected weight loss drugs remain favored over newer oral treatments by a significant margin, with Eli Lilly’s Zepbound leading the pack, according to a survey of healthcare specialists by Spherix Global Insights.